-- 摩根士丹利週三在一份電子郵件報告中指出，富蘭克林資源公司 (BEN) 正展現出「早期復甦」的跡象，核心資金流入的改善和西部資產管理公司 (Western Asset Management) 資金流出的緩解增強了其業務成長勢頭。 這家投資銀行表示，富蘭克林資源公司已連續九個季度實現「淨正流入」（不包括西部資產管理公司），而與西部資產管理公司相關的季度資金流出已從一年前約680億美元的峰值降至約40億美元。 報告指出，富蘭克林資源公司“向高成長領域重新定位”，包括獨立管理帳戶、ETF和另類投資，正在幫助其穩定“發展軌跡”，但“費用壓縮”和向“低費用產品”的轉型仍然是結構性挑戰。 摩根士丹利將富蘭克林資源公司的評級從“減持”上調至“中性”，並將目標價從21美元上調至31美元，理由是“資金流動動態”的改善和風險回報狀況的更加平衡。
Price: $31.13, Change: $+0.67, Percent Change: +2.20%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%